Efficacy of Morning Versus Evening Latanoprost/Timolol Fixed Combination for Open-Angle Glaucoma and Ocular Hypertension: A Randomized Clinical Trial

Overview

Journal Transl Vis Sci Technol

Specialties Biomedical Engineering
Ophthalmology

Date 2024 Jan 29

PMID 38285464

Authors

Hui Feng

Dong Han

Wensheng Lu

Guangxian Tang

Hengli Zhang

Sujie Fan

Aiguo Lv

Jing Jiang

Qing Zhang

Ye Zhang

Kai Cao

Zhi Li

Shuning Li

Affiliations

Soon will be listed here.

Abstract

Purpose: To compare the efficacy of morning and evening latanoprost/timolol fixed-combination (LTFC) dosing in patients with primary open-angle glaucoma (POAG) and ocular hypertension.

Methods: In this double-blind, randomized clinical trial, 63 untreated Chinese patients with POAG and ocular hypertension were enrolled. All patients received LTFC and were randomized (1:1) to group 1, morning (8 AM) dosing, or group 2, evening (8 PM) dosing. Vehicle drops were used in the morning or evening, accordingly, to preserve masking. Patients were treated for 4 weeks. Outcomes included mean reduction of the 24-hour intraocular pressure (IOP) and IOP fluctuation from baseline after a 4-week treatment.

Results: Fifty-six patients were included in the final analysis. In both groups, the posttreatment IOP values were significantly lower than those at baseline at each 24-hour measuring time point. A significant difference between the groups in IOP reduction from baseline was observed at the 9:30 AM time point (4.01 ± 2.62 vs. 2.42 ± 3.23 mm Hg, evening dosing versus morning dosing group; P = 0.048). Both groups showed decreased IOP fluctuation after treatment. However, the morning dosing group had a significantly greater decrease in diurnal IOP fluctuation than that of the evening dosing group (2.04 ± 2.32 mm Hg vs. 0.50 ± 1.70 mm Hg, respectively; P = 0.012).

Conclusions: Both morning and evening LTFC dosing can effectively reduce 24-hour IOP and IOP fluctuation. Morning dosing is more likely to effectively control diurnal IOP fluctuations.

Translational Relevance: This multicenter, double-blind, randomized clinical trial generates robust evidence on the optimal LTFC dosing regimen to help clinical decision-making in the treatment of raised IOP.

References

. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000; 130(4):429-40. DOI: 10.1016/s0002-9394(00)00538-9. View

Leske M, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E . Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003; 121(1):48-56. DOI: 10.1001/archopht.121.1.48. View

Garway-Heath D, Crabb D, Bunce C, Lascaratos G, Amalfitano F, Anand N . Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2014; 385(9975):1295-304. DOI: 10.1016/S0140-6736(14)62111-5. View

Diestelhorst M, Larsson L . A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2005; 113(1):70-6. DOI: 10.1016/j.ophtha.2005.06.027. View

Konstas A, Maltezos A, Gandi S, Hudgins A, Stewart W . Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999; 128(1):15-20. DOI: 10.1016/s0002-9394(99)00073-2. View

Caprioli J, Coleman A . Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2007; 115(7):1123-1129.e3. DOI: 10.1016/j.ophtha.2007.10.031. View

Wang N, Friedman D, Zhou Q, Guo L, Zhu D, Peng Y . A population-based assessment of 24-hour intraocular pressure among subjects with primary open-angle glaucoma: the handan eye study. Invest Ophthalmol Vis Sci. 2011; 52(11):7817-21. DOI: 10.1167/iovs.11-7528. View

Sharif N, Crider J, Husain S, Kaddour-Djebbar I, Ansari H, Abdel-Latif A . Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003; 19(5):437-55. DOI: 10.1089/108076803322473006. View

Zhai R, Cheng J, Xu H, Fang Z, Chen X, Qiu S . Mean amplitude of intraocular pressure excursions: a new assessment parameter for 24-h pressure fluctuations in glaucoma patients. Eye (Lond). 2020; 35(1):326-333. PMC: 7852691. DOI: 10.1038/s41433-020-0845-9. View

10.

Konstas A, Boboridis K, Tzetzi D, Kallinderis K, Jenkins J, Stewart W . Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 2005; 123(7):898-902. DOI: 10.1001/archopht.123.7.898. View

11.

Pachimkul P, Yuttitham K, Thoophom P . 24-Hour intraocular pressure control between travoprost/timolol fixed combination, latanoprost/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension. J Med Assoc Thai. 2011; 94 Suppl 2:S81-7. View

12.

Magacho L, Reis R, Shetty R, Santos L, Avila M . Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006; 113(3):442-5. DOI: 10.1016/j.ophtha.2005.11.011. View

13.

Seibold L, DeWitt P, Kroehl M, Kahook M . The 24-Hour Effects of Brinzolamide/Brimonidine Fixed Combination and Timolol on Intraocular Pressure and Ocular Perfusion Pressure. J Ocul Pharmacol Ther. 2017; 33(3):161-169. PMC: 5385426. DOI: 10.1089/jop.2016.0141. View

14.

Topper J, Brubaker R . Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985; 26(10):1315-9. View

15.

Takmaz T, Asik S, Kurkcuoglu P, Gurdal C, Can I . Comparison of intraocular pressure lowering effect of once daily morning vs evening dosing of latanoprost/timolol maleate combination. Eur J Ophthalmol. 2008; 18(1):60-5. DOI: 10.1177/112067210801800110. View

16.

Liu J, Zhang X, Kripke D, Weinreb R . Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest Ophthalmol Vis Sci. 2003; 44(4):1586-90. DOI: 10.1167/iovs.02-0666. View

17.

Grippo T, Liu J, Zebardast N, Arnold T, Moore G, Weinreb R . Twenty-four-hour pattern of intraocular pressure in untreated patients with ocular hypertension. Invest Ophthalmol Vis Sci. 2012; 54(1):512-7. PMC: 3558295. DOI: 10.1167/iovs.12-10709. View

18.

Fang Z, Wang X, Qiu S, Sun X, Chen Y, Xiao M . 24-h intraocular pressure patterns measured by Icare PRO rebound in habitual position of open-angle glaucoma eyes. Graefes Arch Clin Exp Ophthalmol. 2021; 259(8):2327-2335. DOI: 10.1007/s00417-021-05192-2. View

19.

Pfeiffer N . A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol. 2002; 240(11):893-9. DOI: 10.1007/s00417-002-0553-0. View

20.

Konstas A, Nakos E, Tersis I, Lallos N, Leech J, Stewart W . A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002; 133(6):753-7. DOI: 10.1016/s0002-9394(02)01460-5. View